Part VIII · Therapeutic foundations · Chapter 45

Cytotoxic chemotherapy

The lesion each drug makes, and why it predicts both the resistance and the toxicity.

1 · Major drug classes and mechanisms

Cytotoxic drugs are usefully sorted by the lesion they make rather than by the era they arrived in. The lesion predicts the resistance mechanism and it predicts the dose-limiting toxicity, so one fact does two jobs.

Anthracyclines poison topoisomerase II, intercalate into DNA and generate reactive oxygen species. The first of those is the antitumour mechanism. The third is the cardiac one, which is why cardiac risk tracks cumulative dose rather than dose intensity1.

Taxanes stabilise microtubules and arrest cells in mitosis. Neuropathy follows from the same mechanism acting on axonal transport in long sensory neurons, which is why it is cumulative and frequently irreversible2.

Non-taxane microtubule agents destabilise rather than stabilise. Eribulin inhibits microtubule dynamics through a distinct mode, and it retains activity after taxane exposure3.

Alkylating agents and platinum salts create adducts and interstrand crosslinks that require homologous recombination for repair. That is why germline BRCA status predicts platinum benefit and why a genomic scar score does not4.

Antimetabolites act in S phase. Capecitabine is a prodrug, so its exposure depends on host enzyme activity rather than on tumour biology. Dihydropyrimidine dehydrogenase deficiency is a germline property of the patient, and genotype-guided dosing reduces the toxicity that follows from it5.

The organising claim is that each class has a matched pair of consequences. A drug that damages DNA is escaped by repair. A drug that acts on the spindle is escaped by efflux or by not dividing. Neither is escaped the way a targeted agent is, which is why no assay predicts cytotoxic sensitivity in this disease.

2 · Regimen selection and scheduling

The adjuvant meta-analyses settle more than the individual trials do, and one result inside them is almost never quoted. The earliest overviews established that polychemotherapy reduces recurrence and mortality before any regimen comparison could6,7.

Adding four cycles of a taxane to a fixed anthracycline-based regimen reduced breast cancer mortality. The rate ratio was 0.86 with a standard error of 0.04. Some trials counterbalanced those extra taxane cycles in the control arm with extra cycles of other cytotoxic drugs, roughly doubling the non-taxane dose. In those trials there was no significant difference, with a rate ratio of 0.94 and a standard error of 0.068. Part of what looks like a taxane class effect in the first comparison is a total-dose effect.

The same analysis separates regimens by cumulative dose rather than by name. Standard four-cycle anthracycline and cyclophosphamide was equivalent to standard CMF, with a rate ratio of 0.98. The trials behind that row agree. Four cycles of doxorubicin and cyclophosphamide matched six of CMF in NSABP B-159, and the two did not differ in premenopausal node-positive women in another trial10. Intensifying cyclophosphamide within the doxorubicin combination improved nothing11. Higher-dose epirubicin with cyclophosphamide beat classical CMF, and the lower epirubicin dose did not, which is a dose-response inside one trial12. Anthracycline regimens with substantially higher cumulative dose were superior to standard CMF, with a rate ratio of 0.78 and a standard error of 0.068. Regimen names encode dose, and comparisons between names are often comparisons between doses.

Schedule is a separate axis from dose. Weekly paclitaxel after standard adjuvant doxorubicin and cyclophosphamide improved disease-free and overall survival compared with paclitaxel every three weeks, with an odds ratio for survival of 1.32. Grade 2, 3 or 4 neuropathy was more common on the weekly schedule, at 27% against 20%13. More frequent administration of a spindle agent buys efficacy and costs nerve. With longer follow-up the advantage persisted in smaller form, and an exploratory analysis suggested a substantial benefit in triple-negative disease14.

Other additions have been tested and mostly failed. Docetaxel added to doxorubicin and cyclophosphamide improved five-year disease-free survival from 68% to 75% against fluorouracil in the same combination15. Capecitabine added to a docetaxel, epirubicin and cyclophosphamide regimen did not significantly improve recurrence-free survival16. Capecitabine as a substitute did worse. GEICAM/2003-10 randomised 1,384 node-positive patients to epirubicin and cyclophosphamide followed by docetaxel, or to epirubicin with docetaxel followed by capecitabine17. Five-year invasive disease-free survival was 86% against 82% in favour of the standard sequence, and overall survival did not differ significantly. How much any of this matters depends on receptor status. In node-positive disease, the gains from successive generations of chemotherapy were concentrated in ER-negative tumours18.

Platinum is a selection question rather than a scheduling question in advanced triple-negative disease, and the selection that works is germline BRCA status4.

3 · Dose intensity, dose density, and dose modification

Three quantities are routinely conflated and they come apart in practice. Dose intensity is dose per unit time. Dose density is the same total dose delivered at shorter intervals. Cumulative dose is the total received over the course. A regimen can raise one and lower another.

The randomised demonstration compared dose-dense and conventionally scheduled adjuvant therapy in node-positive disease. Dose-dense treatment improved disease-free survival, with a risk ratio of 0.74, and overall survival, with a risk ratio of 0.69. Four-year disease-free survival was 82% against 75%. There was no difference between concurrent and sequential administration and no interaction between density and sequence. Severe neutropenia was less frequent on the dose-dense regimens than on the conventional ones19. The last of those is counterintuitive and it is the reason the strategy was adoptable.

NSABP B-30 asked the sequencing question with docetaxel. It randomised 5351 women with node-positive disease to four cycles of doxorubicin and cyclophosphamide followed by four of docetaxel, to doxorubicin with docetaxel, or to all three drugs together20. Eight-year overall survival was 83% with the sequential regimen and 79% with each of the others. The hazard ratio for death was 0.83 against doxorubicin with docetaxel, and 0.86, not significant, against the three-drug regimen. Disease-free survival favoured the sequential regimen over both. In premenopausal women, amenorrhoea lasting six months or more was associated with better survival in every arm, whatever the oestrogen receptor status.

The patient-level meta-analysis puts a size on it. Data were available for 37,298 of 40,070 women randomised in 26 trials. Ten-year recurrence risk was 28.0% with dose-intense treatment against 31.4% with standard scheduling, giving a rate ratio of 0.86 and a 95% confidence interval of 0.82 to 0.89. Ten-year breast cancer mortality was 18.9% against 21.3%, and all-cause mortality was 22.1% against 24.8%. In the seven trials comparing two-weekly with three-weekly delivery of the same chemotherapy, ten-year recurrence was 24.0% against 28.3% among 10,004 women21.

The objection this is usually met with is that intensification kills people. The meta-analysis answers it directly. Ten-year risk of death without recurrence was 4.1% with dose-intense treatment and 4.6% with standard scheduling, with a rate ratio of 0.88 and an interval of 0.78 to 0.9921. Mortality from causes other than breast cancer was not higher.

Dose modification is where planned intensity is lost silently. A reduction made during a toxicity episode commonly persists after the toxicity has resolved. The reasoning for treating delivered dose as a standing question rather than an assumption is in Distinguishing resistance from under-dosing, non-adherence, and pseudo-progression.

4 · Neoadjuvant and adjuvant applications

The drugs are the same and the information is not. Preoperative treatment converts a course of chemotherapy into an experiment with a tissue readout, and that readout, residual cancer burden, is what later escalation is built on.

Three trials instantiate the same structure with three different classes. In CREATE-X, capecitabine after residual invasive disease improved five-year disease-free survival, with a hazard ratio for recurrence, second cancer or death of 0.70 and a 95% confidence interval of 0.53 to 0.92. Five-year overall survival was 89.2% against 83.6%, with a hazard ratio for death of 0.59. In the triple-negative subgroup, disease-free survival was 69.8% against 56.1% and overall survival was 78.8% against 70.3%22. In KATHERINE, a conjugate replaced trastuzumab after residual HER2-positive disease23 Antibody-drug conjugates and targeted delivery. In KEYNOTE-522, checkpoint blockade was added before surgery and continued after it24,25 Immunotherapy.

The common element is worth naming, because later chapters instantiate it repeatedly. Observed response to treatment is a stronger selection variable in this disease than any baseline biomarker currently available. The de-escalation and escalation framework that follows from that is set out in Principles of multidisciplinary treatment.

Two cautions belong with it. Pathologic complete response is defined by a sampling protocol, so how much of the bed was examined affects the answer. And a trial that escalates only non-responders tells you nothing about whether the escalation would have helped the responders.

5 · Metastatic use and cumulative exposure

The goal changes and so does the arithmetic. Sequential single agents are preferred over combinations unless a rapid response is needed for organ function, because combinations raise response rate and toxicity without reliably extending survival.

The combination trials show that pattern and its two exceptions. Docetaxel with doxorubicin lengthened time to progression over doxorubicin with cyclophosphamide, without a survival difference26. Epirubicin with paclitaxel was no better than epirubicin with cyclophosphamide27. Docetaxel with epirubicin and docetaxel with capecitabine were similarly effective with different toxicity28, and paclitaxel with epirubicin matched paclitaxel with carboplatin29. The exceptions were combinations against a single agent in anthracycline-pretreated disease. Docetaxel with capecitabine lengthened median survival from 11.5 to 14.5 months against docetaxel alone30, and gemcitabine with paclitaxel lengthened it from 15.8 to 18.6 months against paclitaxel alone31. Capecitabine alone improved survival over classical CMF by being similarly active and less toxic32. The case for single agents was argued on the same ground. In palliative treatment, the argument ran, toxicity has to be weighed against symptom relief, and gemcitabine was developed as a single agent on that basis33.

Among single agents, schedule and formulation matter. Weekly paclitaxel was active in pretreated disease34. Nanoparticle albumin-bound paclitaxel gave a higher response rate than standard paclitaxel, 33% against 19%35, and weekly dosing gave longer progression-free survival than docetaxel36. Pegylated liposomal doxorubicin matched doxorubicin with much less cardiotoxicity37. Weekly low-dose epirubicin preserved efficacy38, and above a certain dose epirubicin added toxicity without efficacy39. Vinorelbine remained active after anthracyclines and taxanes40. Ixabepilone was active first line after adjuvant anthracycline, and after taxane or multiple-agent resistance41,42,43. Capecitabine at 1,000 mg/m2 twice daily was safe in older women44. A fixed dose of 1,500 mg twice daily on a seven-days-on, seven-off schedule was less toxic than standard dosing with similar efficacy in X-7/745.

Bevacizumab lengthened progression-free survival with paclitaxel, from 5.9 to 11.8 months, without lengthening overall survival46. RIBBON-1 found the same with capecitabine, taxane or anthracycline partners47.

The benchmark for late-line single-agent chemotherapy is lower than most conversations assume. One randomised trial compared sacituzumab govitecan with physician's choice of eribulin, vinorelbine, capecitabine or gemcitabine in relapsed metastatic triple-negative disease. Median progression-free survival on the chemotherapy arm was 1.7 months in 233 patients, with a 95% confidence interval of 1.5 to 2.648. That figure is the comparator against which newer classes should be read.

Eribulin is the one agent with a survival result in heavily pretreated disease. Among 762 women randomised 2:1, median overall survival was 13.1 months with eribulin against 10.6 months with physician's choice. The hazard ratio for death was 0.81, with a 95% confidence interval of 0.66 to 0.99. Peripheral neuropathy was the commonest reason for discontinuing eribulin, in 24 of 503 patients treated3.

Cumulative exposure constrains the sequence in three ways. Anthracycline cardiac risk tracks lifetime dose1. Taxane neuropathy accumulates and often does not resolve2. And conjugates now occupy lines that single-agent chemotherapy used to occupy, so cumulative payload exposure has become a version of the same constraint in a new class Payload class, cross-resistance, and sequencing between conjugates.

Body surface area is a poor proxy for the volume in which a drug distributes. Sarcopenia was a determinant of chemotherapy toxicity and of time to tumour progression in metastatic breast cancer49, which means two patients with the same calculated dose can receive quite different exposures.

6 · Resistance mechanisms

Cytotoxic resistance is less often a single lesion than targeted-agent resistance, which is the main reason no assay predicts it. Four mechanisms account for most of it and they are not mutually exclusive.

Efflux moves drug out of the cell. The transporters that do it, including MDR1 and ABCC1, are the same ones that defeat conjugate payloads50,51, which is why conjugate and chemotherapy resistance are not independent problems.

Target alteration changes what the drug acts on. Tubulin isotype composition alters taxane binding, and topoisomerase II level alters anthracycline effect. Neither is measured routinely.

Repair capacity determines what a DNA lesion costs. Restoration of homologous recombination removes platinum sensitivity and PARP inhibitor sensitivity together52, and the detailed argument is in PARP inhibitor and platinum resistance, including restoration of repair.

Drug-tolerant states account for the rest and they are not genetic. A small subpopulation survives through a reversible chromatin-mediated state53. Cells in that state acquire a different dependency, which is itself targetable54. Rare cell variability precedes and predicts which cells will reprogram55. Persisters cycle rather than simply resting56. Metabolic state contributes, with MYC and MCL1 cooperating to sustain chemotherapy-resistant populations through mitochondrial oxidative phosphorylation57.

One immune-adjacent mechanism belongs here rather than in Immunotherapy. CD73 promotes anthracycline resistance and poor prognosis in triple-negative disease58, which means a single molecule links cytotoxic escape and adenosine-mediated immune suppression.

The taxonomy that puts these in clinical order, and distinguishes a population that was never sensitive from one that was made resistant, is in A working taxonomy, intrinsic, adaptive, and acquired resistance.

7 · Toxicity mitigation and supportive standards

Four areas have evidence worth acting on, and they differ in how much they change.

Myelosuppression. Growth factor support makes shorter intervals deliverable, and the randomised evidence is that severe neutropenia was less frequent on supported dose-dense regimens than on conventional ones19. The supportive drug changed which schedules were possible rather than making an existing schedule safer.

Alopecia. Scalp cooling has two prospective datasets. In a randomised trial stopped early for efficacy, hair was preserved in 48 of 95 women who received cooling, which is 50.5%, and in 0 of 47 who did not59. In a prospective cohort, hair loss of 50% or less occurred in 67 of 101 evaluable women with cooling and 0 of 16 controls. No participant in the cooling group in that study received an anthracycline60. That exclusion is the reading caution, because it is the anthracycline-containing regimens where patients most want the intervention.

Neuropathy. There is no established preventive agent, so dose modification and schedule choice are the intervention2. Telling a patient that nothing prevents it, early, is more useful than adding a supplement.

Host genotype. Fluoropyrimidine toxicity is partly predictable before the first dose, and genotype-guided dosing based on DPYD reduces it5. This is one of the few places in this chapter where a pre-treatment test changes a decision.

In practice

Three questions are worth asking before each cycle, and none of them is on a standard toxicity form.

What proportion of the planned dose has actually been delivered so far, counting reductions and delays. Planned intensity and received intensity diverge quietly Distinguishing resistance from under-dosing, non-adherence, and pseudo-progression.

Is the current reduction still needed. Reductions made for a resolved episode tend to persist for the rest of the course.

Which toxicity is cumulative and which is not. Neuropathy and cardiac injury accumulate, so a tolerable cycle four is not evidence about cycle eight. Myelosuppression does not accumulate the same way, so it can be managed cycle by cycle.

Cardiac surveillance belongs in the first year after anthracycline exposure. In a cohort of 2625 patients, 98% of cardiotoxicity events occurred within that year. Median onset was 3.5 months after the end of chemotherapy. Recovery was more likely when heart failure therapy was started early1.

Interplay

Cytotoxic therapy is the least selective agent in the book and it still selects. It kills dividing cells, so it enriches for the compartment that is not dividing, and the drug-tolerant states above are exactly that compartment. A heterogeneous tumour therefore survives chemotherapy through a different subpopulation than it survives targeted therapy through, which is why sequence of class changes what is left behind.

See Integrative biological interplay

References

All 60 references
  1. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015 131:1981-1988. PMID 25948538
  2. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020 38:3325-3348. PMID 32663120
  3. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011 377:914-923. PMID 21376385
  4. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 2018 24:628-637. PMID 29713086
  5. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018 19:1459-1467. PMID 30348537
  6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998 352:930-42. PMID 9752815
  7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365:1687-717. PMID 15894097
  8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012 379:432-444. PMID 22152853
  9. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990 8:1483-96. PMID 2202791
  10. Bang SM, Heo DS, Lee KH, et al. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000 89:2521-6. PMID 11135211
  11. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997 15:1858-69. PMID 9164196
  12. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001 19:3103-10. PMID 11408507
  13. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008 358:1663-1671. PMID 18420499
  14. Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 2015 33:2353-60. PMID 26077235
  15. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005 352:2302-13. PMID 15930421
  16. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012 30:11-8. PMID 22105826
  17. Martín M, Ruiz Simón A, Ruiz Borrego M, et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. J Clin Oncol 2015 33:3788-95. PMID 26416999
  18. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006 295:1658-67. PMID 16609087
  19. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003 21:1431-1439. PMID 12668651
  20. Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010 362:2053-65. PMID 20519679
  21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019 393:1440-1452. PMID 30739743
  22. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017 376:2147-2159. PMID 28564564
  23. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019 380:617-628. PMID 30516102
  24. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020 382:810-821. PMID 32101663
  25. Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 2024 391:1981-1991. PMID 39282906
  26. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003 21:968-75. PMID 12637459
  27. Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 2005 23:8322-30. PMID 16293863
  28. Mavroudis D, Papakotoulas P, Ardavanis A, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010 21:48-54. PMID 19906761
  29. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004 15:1517-26. PMID 15367413
  30. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002 20:2812-23. PMID 12065558
  31. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008 26:3950-7. PMID 18711184
  32. Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011 29:4498-504. PMID 22025143
  33. Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001 15:11-4. PMID 11252882
  34. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001 19:4216-23. PMID 11709565
  35. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005 23:7794-803. PMID 16172456
  36. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009 27:3611-9. PMID 19470941
  37. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004 15:440-9. PMID 14998846
  38. Gasparini G, Dal Fior S, Panizzoni GA, Favretto S, Pozza F. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 1991 14:38-44. PMID 1987737
  39. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996 14:1146-55. PMID 8648369
  40. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001 92:2267-72. PMID 11745280
  41. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007 25:3415-20. PMID 17606972
  42. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007 25:3399-406. PMID 17606975
  43. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007 25:3407-14. PMID 17606974
  44. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005 23:2155-61. PMID 15710946
  45. Khan QJ, Bohnenkamp C, Monson TE, et al. Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial. JCO Oncol Adv 2025 2:e2400068. PMID 39917581
  46. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 357:2666-76. PMID 18160686
  47. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011 29:1252-60. PMID 21383283
  48. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021 384:1529-1541. PMID 33882206
  49. Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009 15:2920-2926. PMID 19351764
  50. Li G, Guo J, Shen BQ, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther 2018 17:1441-1453. PMID 29695635
  51. Loganzo F, Tan X, Sung M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 2015 14:952-963. PMID 25646013
  52. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008 451:1116-1120. PMID 18264087
  53. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010 141:69-80. PMID 20371346
  54. Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 2017 551:247-250. PMID 29088702
  55. Shaffer SM, Dunagin MC, Torborg SR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 2017 546:431-435. PMID 28607484
  56. Oren Y, Tsabar M, Cuoco MS, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 2021 596:576-582. PMID 34381210
  57. Lee KM, Giltnane JM, Balko JM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab 2017 26:633-647. PMID 28978427
  58. Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013 110:11091-11096. PMID 23776241
  59. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 2017 317:596-605. PMID 28196254
  60. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017 317:606-614. PMID 28196257